版本:
中国

BRIEF-Trillium Therapeutics presents TTI-621 preclinical data at AACR annual meeting

April 3 Trillium Therapeutics Inc:

* Trillium Therapeutics presents TTI-621 preclinical data at AACR annual meeting and provides clinical update

* Trillium Therapeutics-currently enrolling patients in expansion phase of ongoing phase 1 trial of tti-621, in patients with multiple Hematologic malignancies

* Trillium therapeutics inc - to date, 33 evaluable patients have been enrolled into expansion phase of tti-621 trial Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐